Leukemia News

SAN DIEGO — Non-Hispanic Black patients with acute myeloid leukemia experienced the largest improvement in OS since the approval of venetoclax-based front-line therapy, according to data presented at ASH Annual Meeting and Exposition.

Revumenib proved safe and effective among pediatric and adult patients with relapsed or refractory KMT2Ar acute myeloid leukemia and acute lymphoid leukemia, according to study results presented at ASH Annual Meeting and Exhibition.

In a special scientific session on race and science at ASH Annual Meeting an Exposition, Saad Z. Usmani, MD, MBA, FACP, FRCP, examined clinical trial inclusion from an investigator’s perspective.

SAN DIEGO — Individuals treated with first-generation Bruton tyrosine kinase inhibitors with preexisting cardiovascular disease had significantly higher odds of developing cardiovascular adverse events, study results showed.

SAN DIEGO — A combination of targeted therapies used for a response-directed duration significantly improved outcomes compared with chemoimmunotherapy for fit patients with untreated chronic lymphocytic leukemia, according to study results.

SAN DIEGO — Individuals with sickle cell trait are at increased risk for leukemia, specifically myeloid and monocytic leukemias, according to data presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Oral arsenic trioxide proved safe and effective when used as part of a regimen for treatment of acute promyelocytic leukemia, study results presented at ASH Annual Meeting and Exhibition showed.

Social determinants of health for children and young adults with leukemia and lymphoma must be researched as much as the diseases themselves to improve care, according to a presenter at ASH Annual Meeting and Exposition.

Outcomes among children with acute myeloid leukemia treated with high-dose cytarabine-based regimens did not vary by race, according to study results presented at ASH Annual Meeting and Exposition.

Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 9-12 in San Diego.